Loading organizations...
Key people at MedAvante.
MedAvante developed and deployed technology-enabled solutions for central nervous system (CNS) clinical trials, specializing in centralized psychiatric and neurocognition rating and monitoring services. The company built platforms designed to standardize patient assessment and enhance signal detection, aiming to improve data quality and consistency in complex drug development studies. Their core capabilities included rigorous rater training and real-time data capture mechanisms tailored for mental health and neurological research.
The company was founded in 2002 by Paul Gilbert and Amy Ellis. Their founding insight centered on the critical need to transform the accuracy and reliability of psychiatric and neurological clinical trials. Recognizing the inherent subjectivity in traditional assessment methods, Gilbert and Ellis envisioned and launched innovative approaches to standardize clinical endpoints, thus accelerating the development of new treatments for debilitating CNS disorders.
MedAvante’s services were utilized by pharmaceutical companies and contract research organizations conducting clinical trials globally. The firm's vision was to enhance the precision and integrity of clinical research data, ultimately fostering more efficient and successful development of therapies for patients suffering from brain-related conditions. The company aimed to contribute to a future where new CNS treatments could be brought to market with greater confidence and speed.
MedAvante, now operating as MedAvante-ProPhase and part of WCG Clinical, is a healthcare services company specializing in clinical trial operations, particularly for central nervous system (CNS) and behavioral health studies.[1][2] Founded in 2002 and based in Trenton, New Jersey, it provides end-to-end solutions including study planning, site feasibility analysis, trial design, protocol planning, quality oversight, statistical consulting, clinical endpoints assessment, patient recruitment, retention, and study analytics, serving research sponsors, contract research organizations (CROs), and research sites.[1] These services integrate tools for cognitive assessment, data analysis, and management to improve signal detection in trials, addressing challenges like dementia detection, cognitive training, and neurodegenerative disorders amid rising geriatric populations and healthcare tech advancements.[1]
The company solves key pain points in clinical trials by enhancing accuracy, reducing human error through automated scoring, and supporting faster therapy delivery to patients.[1][2] It has demonstrated strong growth, recognized as one of New Jersey's fastest-growing companies, and was acquired by WCG alongside ProPhase to lead in CNS and behavioral health markets.[2][6]
MedAvante was founded in 2002 in Trenton, New Jersey, initially focusing on connecting blinded, independent expert clinicians with investigative research sites for direct subject interviews and assessments in clinical trials.[1][6] The company evolved by expanding into comprehensive clinical trial services, particularly emphasizing CNS and behavioral health, driven by market needs like growing dementia prevalence and cognitive disorder detection.[1]
A pivotal moment came with its acquisition by WCG (WIRB-Copernicus Group), alongside ProPhase, which positioned the combined entity—MedAvante-ProPhase—as a market leader in specialized assessments; this move integrated it into WCG's broader mission of transforming drug development since 2012, leveraging 55 years of predecessor expertise to serve over 5,000 biopharma companies and millions of patients.[2] Post-acquisition, leadership enhancements included appointing Dr. Jeffrey Litwin as CEO of the combined company and adding prominent thought leaders in areas like Alzheimer's, schizophrenia, and ADHD.[2][4]
MedAvante-ProPhase rides the wave of digital transformation in clinical trials, fueled by aging populations, rising dementia prevalence, and demand for cognitive assessment tools amid technological advancements like mobile IT and automated scoring.[1] Its timing aligns with market forces such as increasing R&D spending, regulatory pressures for quality/compliance, and the need to accelerate therapies—reducing trial times and costs while improving accuracy in high-failure CNS studies.[1][2][5]
As part of WCG, it influences the ecosystem by integrating with quality management (via Avoca acquisition) and study start-up solutions, enabling biopharma/CROs to deliver treatments faster to millions of patients and setting standards for CNS trial innovation.[2][5] This positions it centrally in the $50B+ clinical trials sector, where outsourced services grow via tech-enabled efficiency.[3][5]
MedAvante-ProPhase is poised for expansion within WCG's integrated platform, capitalizing on AI-driven assessments, remote monitoring, and decentralized trials to dominate CNS/behavioral health niches.[1][2] Trends like personalized medicine, real-world evidence, and global regulatory harmonization will shape its path, potentially amplifying impact through partnerships and further acquisitions amid escalating healthcare R&D.[1][5]
Its influence may evolve from specialized provider to ecosystem orchestrator, driving higher trial success rates and faster patient access—reinforcing its role as a high-growth leader born from clinician-site connections two decades ago.[2][6]
Key people at MedAvante.
